FacebookLinkedInRssXYouTube

cholesterol-reducing drugs

Esperion Secures $50 Million To Finance Sales Expansion To Asia, Middle East

ANN ARBOR—Esperion Therapeutics, developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling $50 million. The remaining funds are being released sooner than expected and in parallel

By |2021-04-30T14:14:14-04:00April 30th, 2021|Entrepreneurs, Life Sciences|
Read More

Esperion To Grant 75,000 Shares To 18 New Employees

ANN ARBOR—Esperion Therapeutics Inc., a developer of a new class of cholesterol-reducing drugs, announced that the compensation committee of its board of directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units (RSUs) to 18 new employees under Esperion’s 2017 Inducement Equity Incentive Plan.

By |2019-09-05T20:37:09-04:00September 5th, 2019|Clean Update|
Read More